Company: BSX
Filing Date: 2025-02-24
Form Type: 424B2
Source: 0001104659-25-016521
Chunk: 14

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-24
Form: 424B2
Chunk 14
---
<div align='center'>S-4</div>

TABLE OF CONTENTS

cannot assure you that a liquid market for any series will develop or be maintained.

#### ISIN
XS2993376693, for the 2031 Notes.

XS2993380885, for the 2034 Notes.

#### Common Code
299337669, for the 2031 Notes.

299338088, for the 2034 Notes.

#### Denomination and Form
The terms of the notes provide that notes will be issued with a minimum denomination of €100,000 and multiples of €1,000 in excess thereof. The notes of each series will be issued in the form of one or more global notes in fully registered form, without coupons, and will be deposited with, or on behalf of, a common depositary, and registered in the name of the nominee of the common depositary, for, and in respect of interests held through, Euroclear and Clearstream. Except as described in “Description of the Notes — Book-Entry procedures,” certificates will not be issued in exchange for beneficial interests in the global notes. See “Description of the Notes — Book-Entry Procedures” for a further discussion.

#### Trustee
U.S. Bank Trust Company, National Association.

#### Registrar and Paying Agent
U.S. Bank Europe DAC.

#### Governing Law
The indenture, the notes and the guarantees will be governed by, and construed in accordance with, the laws of the State of New York.

#### Risk Factors
Investing in the notes involves risks. See “Risk Factors” beginning on page S-6of this prospectus supplement and other information included or incorporated by reference in this prospectus supplement and the accompanying prospectus for a discussion of factors you should carefully consider before deciding to invest in the notes.

<div align='center'>S-5</div>

TABLE OF CONTENTS

### RISK FACTORS
An investment in the notes involves risks. You should consider carefully the risks described below and the other information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus, before making an investment decision, including the risks and uncertainties set forth in Part I, Item 1A. under the heading “Risk Factors” in our 2024 Form 10-K, as well as any other document we may file with the SEC that is incorporated by reference herein. The risks and uncertainties described in this prospectus supplement as well as the documents incorporated by reference herein are not the only ones facing us. Additional